| Product NDC: | 17772-123 |
| Proprietary Name: | OXTELLAR XR |
| Non Proprietary Name: | OXCARBAZEPINE |
| Active Ingredient(s): | 600 mg/1 & nbsp; OXCARBAZEPINE |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 17772-123 |
| Labeler Name: | Supernus |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA202810 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20130117 |
| Package NDC: | 17772-123-01 |
| Package Description: | 100 TABLET in 1 BOTTLE (17772-123-01) |
| NDC Code | 17772-123-01 |
| Proprietary Name | OXTELLAR XR |
| Package Description | 100 TABLET in 1 BOTTLE (17772-123-01) |
| Product NDC | 17772-123 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | OXCARBAZEPINE |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20130117 |
| Marketing Category Name | NDA |
| Labeler Name | Supernus |
| Substance Name | OXCARBAZEPINE |
| Strength Number | 600 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Anti-epileptic Agent [EPC],Decreased Central Nervous System Disorganized Electrical Activity [PE] |